Tweets
In PsA trials, over time the (ACR20) placebo response has increased (15% every 5 yrs)but was not associated with the active treatment effect size. 42 RCTs, the pooled placebo response was 20.3%; pooled treatment effect vs placebo was 27% https://t.co/b9LRpvcTir
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
Adalimumab biosimilar AVT02 equivalent to Originator Humira in Moderate to Severe Chronic Plaque Psoriasis patients with a PASI score at Week 16 of 91.6% for AVT02vs 89.6% for Humira https://t.co/dO4g4aOuON
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
ICYMI: Drug Safety Risk Communication- The 800 lb Gorilla Approach | #RheumNow https://t.co/6iSJjvlFF8 https://t.co/6egrpCVuaG
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
ICYMI: Steroid Poker
https://t.co/kJOmCyIpzM https://t.co/A6EkxcIcHG
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
In a real world study of lupus patients, aspirin use lowered risk of preeclampsia, as did hydroxychloroquine. Risk Factors for preeclampsia were high Dz activity 1st trimester (OR 4.55), BMI >30 (6.14), antiphospholipid synd (8.02), hx preeclampsia (9.8)https://t.co/giBamMAPRM
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
JAMA reports the COVID-19 combined infection- and vaccination-induced seroprevalence estimate in May 2021 was 83.3% By May 2021, there were 2.1 SARS-CoV-2 infections per reported COVID-19 case. https://t.co/bUZ5AqYnxM
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
Pregabalin (lyrica) for Fibromyalgia 75 mg bid; may be increased to max dose 450 mg/d. (Reduce for renal dz). Indications: DM neuropathy/pain, post-herpetic neuralgia, partial seizures. Rare AE: Angioedema, low Plts, ^PR interval, rhabdo, gynecomastia https://t.co/r4cH7n9qWD
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
Watch: Dr. Robert Chao ( @doctorRBC ) reviews a talk given by Dr. Laura Coates entitled, "Towards personalized treatment strategies for psoriatic arthritis", presented at the virtual EULAR 2021 meeting.
https://t.co/7FmZ4BzHwp
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
B-cell depletion therapy with obinutuzumab, a type II anti-CD20 monoclonal antibody, in lupus nephritis patients was shown to be effective in in combination with standard lupus therapies.
https://t.co/pMXWmuJw5Y https://t.co/1raYa1vLtK
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
TICOSPA - Does Treat to Target Work in Spondyloarthritis?
https://t.co/ibavOjmBJd https://t.co/DseCTMRX7J
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
PsABio study-real-world observational study of ustekinumab vs TNF inhibitors in PsA: 868 pts: cDAPSA remission was 14.9% UST vs 19.2% TNFk and Minimal Dz Activity was 26.4% UST vs 30.8% TNFi at 6 months - both were equipotent in PsA https://t.co/RLadZa6YTI https://t.co/I7eKxD3XyI
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
New podcast titled Quackademia available for download wherever you get your podcasts!
https://t.co/Y6Pqko1tYm https://t.co/6RU1nuj7QU
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
